Tigemonam

Tigemonam is a monobactam antibiotic that is synthetically derived. It is primarily used in the treatment of bacterial infections caused by susceptible organisms. Tigemonam is not widely used due to the development of newer, more effective antibiotics.

History[edit | edit source]

Tigemonam was first synthesized in the 1980s as part of a wave of new monobactam antibiotics. These antibiotics were developed in response to the growing problem of antibiotic resistance, with the aim of providing new treatment options for resistant infections.

Pharmacology[edit | edit source]

Tigemonam works by inhibiting the synthesis of the bacterial cell wall, leading to cell death. It is active against a range of Gram-negative bacteria, including Escherichia coli, Klebsiella species, and Proteus species.

Clinical Use[edit | edit source]

Tigemonam is used in the treatment of infections caused by susceptible Gram-negative bacteria. This includes urinary tract infections, lower respiratory tract infections, skin and skin structure infections, and intra-abdominal infections.

Side Effects[edit | edit source]

Like all antibiotics, tigemonam can cause side effects. These can include gastrointestinal disturbances such as nausea and diarrhea, as well as allergic reactions. In rare cases, tigemonam can cause more serious side effects such as Clostridium difficile associated diarrhea.

Resistance[edit | edit source]

Resistance to tigemonam can occur through several mechanisms, including the production of beta-lactamase enzymes that inactivate the drug, and changes in the bacterial cell wall that prevent the drug from reaching its target.